Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggeletopoulou, Ioanna, Konstantakis, Christos, Manolakopoulos, Spilios, Triantos, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487495/
https://www.ncbi.nlm.nih.gov/pubmed/28706414
http://dx.doi.org/10.3748/wjg.v23.i24.4317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487495/
https://www.ncbi.nlm.nih.gov/pubmed/28706414
http://dx.doi.org/10.3748/wjg.v23.i24.4317

Ejemplares similares